Fibrinogen alpha chain and Fibrinogen beta chain (FGA (Fibrinogen alpha chain), FGB (Fibrinogen beta chain))

The fibrinogen alpha chain (FGA) and fibrinogen beta chain (FGB) are two of the three distinct polypeptide components of the plasma glycoprotein fibrinogen, which is synthesized primarily in the liver and circulates in the blood[1][7]. Each fibrinogen molecule consists of two sets of three non-identical chains—alpha (FGA), beta (FGB), and gamma (FGG)—linked by disulfide bonds to form a hexameric structure[1][3][7]. Upon vascular injury, thrombin cleaves short peptides from the N-termini of the alpha and beta chains, exposing polymerization sites that initiate the conversion of soluble fibrinogen to insoluble fibrin, forming the structural matrix of blood clots[1][2][8]. Fibrinogen and its cleavage products are also involved in cell adhesion, wound healing, immune response, and modulation of inflammation[2][6]. Genetic defects or acquired disorders affecting FGA or FGB may cause bleeding diatheses or increase thrombotic risk[4][5][7]. Plasma fibrinogen is a biomarker for both bleeding and thrombosis and serves as a therapeutic and diagnostic target[6][7]. Note: - To obtain structured information, it is best to consider FGA (fibrinogen alpha chain) and FGB (fibrinogen beta chain) as two separate molecular entities for applications such as drug target databases or bioinformatics analyses. - "Fibrinogen" strictly refers to the multichain complex comprising both alpha, beta, and gamma chains. - There is no established singular abbreviation for the combination of the alpha and beta chains only; abbreviations FGA (alpha) and FGB (beta) are standard.

Other names

Fibrinogen A alpha chain (FGA)Fibrinogen B beta chain (FGB)Aα chain (for FGA)Bβ chain (for FGB)Fibrinopeptide A (cleavage product of FGA)Fibrinopeptide B (cleavage product of FGB)

Replacement therapy increases circulating fibrinogen for clot formation. Thrombin cleaves fibrinogen alpha and beta chains to initiate polymerization to fibrin. Antifibrinolytics inhibit plasmin-mediated degradation of fibrin clots.